Oruka Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
996
across all filing types
Latest filing
2025-07-01
Board/Management Inform…
Country
US
United States of America
Listing
US
ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel biologics for chronic skin diseases and other inflammatory conditions. The company applies advanced antibody engineering to validated modes of action to create potentially best-in-class monoclonal antibodies. Its lead program, ORKA-001, targets the IL-23 cytokine for the treatment of moderate-to-severe plaque psoriasis. Oruka's mission is to redefine the standard of care by developing treatments that achieve high rates of complete disease clearance with a significantly reduced dosing frequency, potentially requiring only one or two doses per year.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| CURRENT REPORT | 2025-07-01 | English | |
| OWNERSHIP DOCUMENT | 2025-06-03 | English | |
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2025-06-03 | English | |
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2025-06-03 | English | |
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2025-06-03 | English | |
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2025-06-03 | English |
Browse filings by year
19 years- 2026 22 filings
- 2025 50 filings
- 2024 96 filings
- 2023 16 filings
- 2022 55 filings
- 2021 48 filings
- 2020 48 filings
- 2019 30 filings
- 2018 52 filings
- 2017 57 filings
- 2016 46 filings
- 2015 86 filings
- 2014 59 filings
- 2013 87 filings
- 2012 46 filings
- 2011 39 filings
- 2010 49 filings
- 2009 87 filings
- 2008 23 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 10034302 | CURRENT REPORT | 2025-07-01 | English | ||
| 10034303 | OWNERSHIP DOCUMENT | 2025-06-03 | English | ||
| 10034306 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2025-06-03 | English | ||
| 10034304 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2025-06-03 | English | ||
| 10034305 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2025-06-03 | English | ||
| 10034308 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2025-06-03 | English | ||
| 10034307 | CURRENT REPORT | 2025-06-03 | English | ||
| 10034309 | Major Shareholding Notification 2025 | 2025-05-15 | English | ||
| 10034313 | PROSPECTUS SUPPLEMENT | 2025-05-14 | English | ||
| 10034321 | QUARTERLY REPORT | 2025-05-14 | English | ||
| 10034315 | Major Shareholding Notification 2025 | 2025-05-13 | English | ||
| 10034325 | ANNUAL REPORT | 2025-04-18 | English | ||
| 10034324 | DEFINITIVE ADDITIONAL MATERIALS | 2025-04-18 | English | ||
| 10034329 | PROXY STATEMENT | 2025-04-18 | English | ||
| 10034330 | Regulatory Filings 2025 | 2025-03-12 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Oruka Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32280/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32280 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32280 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32280 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32280}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Oruka Therapeutics, Inc. (id: 32280)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.